Mucinex Childrens Cough and Congestion

Description

Mucinex® Children's Cough & Congestion is a liquid formulation designed for pediatric use in children aged 4 years and older. Each 6.8 FL OZ (201 mL) bottle contains the following active ingredients: Dextromethorphan HBr (5 mg), serving as a cough suppressant; Guaifenesin (100 mg), functioning as an expectorant; and Phenylephrine HCl (2.5 mg), acting as a nasal decongestant. This product is indicated for the relief of chest congestion, breaking up mucus, alleviating a stuffy nose, and controlling cough. The formulation is flavored with Very Berry to enhance palatability. The National Drug Code (NDC) for this product is 63824-947-11.

Uses and Indications

This drug is indicated for the relief of cough associated with minor throat and bronchial irritation, which may occur due to the common cold or inhaled irritants. It assists in loosening phlegm (mucus) and thinning bronchial secretions, thereby facilitating the clearance of bothersome mucus and enhancing the productivity of coughs.

Additionally, this drug temporarily relieves the intensity of coughing and the impulse to cough, which may help children achieve restful sleep. It also alleviates nasal congestion and a stuffy nose associated with colds.

There are no teratogenic or nonteratogenic effects reported for this drug.

Dosage and Administration

The maximum recommended dosage is six doses within a 24-hour period. Dosing should be measured exclusively with the dosing cup provided, and this cup should not be used with any other products to ensure accurate dosing.

For children aged 6 to under 12 years, the recommended dose is 10 mL every 4 hours. For children aged 4 to under 6 years, the appropriate dose is 5 mL every 4 hours. It is important to note that this product is not recommended for use in children under 4 years of age.

Healthcare professionals should advise caregivers to follow these dosing guidelines or any specific instructions provided by a physician.

Contraindications

Use of this product is contraindicated in children who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within 2 weeks of discontinuing such medication. MAOIs are typically prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. If there is uncertainty regarding the presence of an MAOI in a child's prescription, consultation with a healthcare professional is advised prior to administration of this product. Additionally, it is essential to adhere to the recommended dosage and not exceed the directed amount while using this product.

Warnings and Precautions

Use of this product is contraindicated in children who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or have taken one within the past two weeks. MAOIs are commonly prescribed for depression, psychiatric or emotional conditions, and Parkinson's disease. If there is uncertainty regarding the presence of an MAOI in a child's prescription medication, it is imperative to consult a healthcare professional, such as a doctor or pharmacist, prior to administration.

Prior to using this product, it is essential to consult a healthcare provider if the child has any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, a cough that produces excessive phlegm (mucus), or a persistent or chronic cough, such as that associated with asthma.

While using this product, it is critical to adhere strictly to the recommended dosage and not exceed the directed amount.

If any of the following symptoms occur, the use of this product should be discontinued, and a healthcare professional should be consulted: nervousness, dizziness, or sleeplessness. Additionally, if symptoms do not improve within seven days, or if they are accompanied by fever, or if a cough persists for more than seven days, recurs, or occurs with fever, rash, or a persistent headache, these may indicate a serious condition requiring medical evaluation.

This product should be kept out of reach of children. In the event of an overdose, immediate medical assistance should be sought, or contact with a Poison Control Center should be established without delay.

Side Effects

Patients may experience a range of adverse reactions while using this product. Serious adverse reactions warrant immediate medical attention and include symptoms such as nervousness, dizziness, or sleeplessness. If these symptoms occur, patients are advised to discontinue use and consult a healthcare professional. Additionally, if symptoms do not improve within 7 days, or if they are accompanied by fever, patients should seek medical advice. A cough that persists for more than 7 days, recurs, or occurs with fever, rash, or a persistent headache may indicate a serious underlying condition and should be evaluated by a healthcare provider.

Before using this product, it is important for patients to consult a doctor if the child has any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, or a cough that produces excessive phlegm. Furthermore, a persistent or chronic cough, such as that associated with asthma, should also prompt a discussion with a healthcare professional prior to use.

Warnings are in place regarding the use of this product in children who are currently taking or have recently stopped taking a prescription monoamine oxidase inhibitor (MAOI). These medications are typically prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. It is crucial to avoid using this product during MAOI treatment and for at least 2 weeks after discontinuation. If there is uncertainty about whether a child's prescription includes an MAOI, it is recommended to consult a doctor or pharmacist before administration.

Drug Interactions

The concomitant use of this product with monoamine oxidase inhibitors (MAOIs) is contraindicated in pediatric patients. MAOIs are typically prescribed for the treatment of depression, psychiatric disorders, or Parkinson's disease. Administration of this product should be avoided in children who are currently taking an MAOI or have discontinued an MAOI within the past two weeks.

Healthcare providers should ensure that patients and caregivers are informed about the presence of MAOIs in any prescription medications. If there is uncertainty regarding whether a child's prescription includes an MAOI, it is imperative to consult a healthcare professional, such as a doctor or pharmacist, prior to administering this product.

Packaging & NDC

Below are the non-prescription pack sizes of Mucinex Childrens Cough and Congestion (dextromethorphan hydrobromide, guaifenesin, and phenylephrine hydrochloride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should not use this product if they are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within 2 weeks of stopping an MAOI. Prior to use, it is essential to consult a healthcare professional if the child has any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, cough with excessive phlegm, or a persistent cough associated with asthma.

When administering this product, it is crucial to adhere to the recommended dosage and not exceed 6 doses within a 24-hour period. The dosing should be measured using the provided dosing cup, which should not be used with other products. The recommended dosages are as follows: for children aged 6 to under 12 years, 10 mL every 4 hours; for children aged 4 to under 6 years, 5 mL every 4 hours; and this product is not recommended for children under 4 years of age.

Parents and caregivers should monitor for any adverse effects, including nervousness, dizziness, or sleeplessness, and should discontinue use and consult a doctor if symptoms do not improve within 7 days, if the cough persists for more than 7 days, or if it is accompanied by fever, rash, or a persistent headache. It is important to keep this product out of reach of children, and in the event of an overdose, medical assistance or contact with a Poison Control Center should be sought immediately.

Geriatric Use

The prescribing information for Mucinex® Children's Cough & Congestion does not provide specific guidance regarding the use of this medication in geriatric patients. The insert primarily addresses pediatric use and lacks any recommendations concerning age considerations, dosage adjustments, safety concerns, or special precautions that may be relevant for elderly patients.

Healthcare providers should exercise caution when considering the use of this medication in geriatric patients due to the absence of data. It is advisable to monitor elderly patients closely for any potential adverse effects or interactions, given the lack of established safety and efficacy profiles in this population.

Pregnancy

The safety of Mucinex® Children's Cough & Congestion during pregnancy has not been established. Pregnant patients or those planning to become pregnant should consult a healthcare provider before use, as there may be potential risks to the fetus; however, specific studies or data regarding these risks are not provided in the prescribing information.

No specific dosage modifications for pregnant women are mentioned; therefore, it is essential for healthcare professionals to provide guidance tailored to the individual patient's circumstances. Mucinex® Children's Cough & Congestion should be used only if clearly needed and after a thorough discussion with a healthcare professional regarding the potential benefits and risks.

Lactation

There are no specific warnings or recommendations regarding the use of Mucinex® Children's Cough & Congestion in lactating mothers. Additionally, there is no information available concerning the potential for excretion of the medication in breast milk or its effects on breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdose, it is imperative to seek immediate medical assistance or contact a Poison Control Center without delay. Prompt intervention is crucial to mitigate potential adverse effects associated with the overdose.

Healthcare professionals should be aware that the specific symptoms of an overdose may vary depending on the substance involved. Therefore, a thorough assessment of the patient's condition is essential to determine the appropriate course of action.

Management of an overdose typically involves supportive care and symptomatic treatment. Continuous monitoring of the patient's vital signs and clinical status is recommended. In cases where the specific substance is known, targeted interventions may be employed to counteract the effects of the overdose.

It is essential for healthcare providers to remain vigilant and act swiftly in the management of overdose situations to ensure optimal patient outcomes.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available data. Additionally, there is no information regarding nonclinical toxicology or animal pharmacology and toxicology.

Postmarketing Experience

Reports of side effects have been received through voluntary submissions and surveillance programs. Healthcare professionals and patients are encouraged to report any adverse events to the designated contact number provided for this purpose.

Patient Counseling

Healthcare providers should advise patients to keep this product out of reach of children to prevent accidental ingestion. In the event of an overdose, patients should be instructed to seek medical help or contact a Poison Control Center immediately.

It is crucial to inform patients that this product should not be used in children who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within 2 weeks of stopping such medication. Patients should be encouraged to consult with a doctor or pharmacist if they are uncertain whether their child's prescription includes an MAOI.

Patients should be instructed to discontinue use and consult a doctor if they experience nervousness, dizziness, or sleeplessness. Additionally, if symptoms do not improve within 7 days, or if they occur alongside fever, or if a cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or a persistent headache, they should seek medical advice, as these may indicate a serious condition.

While using this product, patients must be reminded not to exceed the recommended dosage. Furthermore, healthcare providers should recommend that patients consult a doctor before use if the child has any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, a cough that produces excessive phlegm, or a persistent or chronic cough, such as that associated with asthma.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a controlled temperature range of 20-25°C (68-77°F). Refrigeration is not recommended, as it may compromise the integrity of the product. Proper handling and storage conditions must be adhered to in order to maintain product efficacy and safety.

Additional Clinical Information

The medication is administered orally. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Mucinex Childrens Cough and Congestion, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)